Craig P. writes, " Seems like the J.P. Morgan Healthcare Conference was nothing but a lot of junk this year. No real news. Probably just another excuse of a conference for J.P. Morgan to entice biotech companies to rob their shareholders blind with more dilutive financings."
C'mon Craig, let's be fair. Biotech CEOs don't need bankers like J.P. Morgan to push them into dilutive financings. They're very happy to do so on their own accord!
Craig is right, the biotech tribe's insanely busy gathering in San Francisco last week did not produce much news, and that was a disappointment. Yet optimism for the biotech sector and the year ahead did seem high. That's a plus, I guess. Of course, those that attended were the Kool-Aid drinkers -- convincing investors who were not in attendance to put money to work in biotech is the real trick.
I'm still working through my notes from last week and doing more research, but some of the stock stories which left me with the warm fuzzies were Medivation (MDVN - Get Report) (I think the Alzheimer's drug Dimebon has a real shot at working); Alkermes (ALKS - Get Report) (a good way to play the FDA's upcoming decision on Exenatide Once Weekly); Gilead Sciences (GILD) (HIV, HIV, HIV); and even Genzyme (GENZ) (I think investors are going to kick out the CEO, Henri Termeer).-- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.